Skip to main content

Advertisement

Table 4 Cox proportional hazards analysis of the impact of SATB1 protein expression on overall survival and recurrence free survival in resected pancreatobiliary type and intestinal type periampullary adenocarcinomas

From: Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma

  OS RFS
Pancreatobiliary type HR (95% CI) n (events) p† HR (95% CI) n (events) p
All cases       
SATB1 neg 1.00 84 (63)   1.00 84 (69)  
SATB1 pos 2.11 (1.25-3.56) 21 (19)   1.87 (1.10-3.18) 21 (18)  
No adjuvant treatment    0.166    0.927
SATB1 neg 1.00 40 (30) 1.00 40 (33)
SATB1 pos 2.94 (1.37-6.29) 9 (9) 1.63 (0.71-3.74) 9 (7)
Any adjuvant treatment     
SATB1 neg 1.00 44 (33) 1.00 44 (36)
SATB1 pos 1.70 (0.83-3.52) 12 (10) 2.05 (1.02-4.11) 12 (11)
No gemcitabine    0.066    0.384
SATB1 neg 1.00 46 (35) 1.00 46 (38)
SATB1 pos 3.14 (1.60-6.16) 12 (12) 2.05 (1.00-4.20) 12 (10)
Gemcitabine     
SATB1 neg 1.00 38 (28) 1.00 38 (31)
SATB1 pos 1.44 (0.62-3.35) 9 (7) 1.60 (0.72-3.56) 9 (8)
Intestinal type       
All cases       
SATB1 neg 1.00 45 (22)   1.00 45 (20)  
SATB1 pos 1.06 (0.47-2.38) 16 (8)   1.26 (0.57-2.77) 16 (9)  
No adjuvant treatment    0.165    0.021
SATB1 neg 1.00 33 (17) 1.00 33 (13)
SATB1 pos 1.62 (0.67-3.92) 10 (7) 2.69 (1.11-6.51) 10 (8)
Any adjuvant treatment     
SATB1 neg 1.00 12 (5) 1.00 12 (7)
SATB1 pos 0.30 (0.03-2.56) 6 (1) 0.18 (0.02-1.46) 6 (1)
No gemcitabine    0.649    0.143
SATB1 neg 1.00 40 (20) 1.00 40 (17)
SATB1 pos 1.20 (0.51-2.83) 12 (7) 1.76 (0.76-4.09) 12 (8)
Gemcitabine     
SATB1 neg 1.00 5 (2) 1.00 5 (3)
SATB1 pos 0.67 (0.06-7.53) 4 (1) 0.27 (0.03-2.64) 4 (1)
  1. P value for term of interaction by Cox multivariable analysis including treatment, SATB1 expression, gemcitabine vs no gemcitabine or any adjuvant vs no adjuvant, and a term of interaction. Bold text indicates significant values.